[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100491750":3},{"organization":4,"armGroups":7,"interventions":17,"overallOfficials":25,"centralContacts":29,"locations":39,"responsibleParty":58,"collaborators":61,"id":65,"slug":66,"hasResults":67,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":33,"eligibilityCriteria":71,"healthyVolunteers":72,"sex":73,"minAge":74,"maxAge":33,"enrollmentInfo":75,"targetDuration":33,"studyType":78,"phases":79,"briefSummary":81,"conditions":82,"keywords":33,"overallStatus":42,"whyStopped":33,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"Yale University","OTHER",[8,13],{"label":9,"type":6,"description":10,"interventionNames":11},"Healthy Volunteers","Healthy volunteers with no current or past major medical or psychiatric history",[12],"Drug: [11C]OMAR",{"label":14,"type":6,"description":15,"interventionNames":16},"Opioid Use Disorder","Patients diagnosed with opioid use disorder",[12],[18],{"type":19,"name":20,"description":21,"armGroupLabels":22,"otherNames":23},"DRUG","[11C]OMAR","For each \\[11C\\]OMAR PET scan, up to 20 mCi of \\[11C\\]OMAR will be administered.",[9,14],[24],"[11C] JHU75528",[26],{"name":27,"affiliation":5,"role":28},"Anahita Bassir Nia, MD","PRINCIPAL_INVESTIGATOR",[30,35],{"name":27,"role":31,"phone":32,"phoneExt":33,"email":34},"CONTACT","203-974-7540",null,"anahita.bassirnia@yale.edu",{"name":36,"role":31,"phone":37,"phoneExt":33,"email":38},"Angelina Contreras","203-626-1105","angelina.contreras@yale.edu",[40],{"facility":41,"status":42,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Connecticut Mental Health Center, Clinical Neuroscience Research Unit","RECRUITING","New Haven","Connecticut","06519","United States","US",{"type":49,"coordinates":50},"Point",[51,52],-72.92816,41.30815,{"lat":52,"lon":51},[55,57],{"name":56,"role":31,"phone":37,"phoneExt":33,"email":38},"Angelina Contreras, BS",{"name":27,"role":28,"phone":33,"phoneExt":33,"email":33},{"type":28,"investigatorFullName":59,"investigatorTitle":60,"investigatorAffiliation":5,"oldNameTitle":33,"oldOrganization":33},"Anahita Bassir Nia","Assistant Professor of Psychiatry",[62],{"name":63,"class":64},"National Institute on Drug Abuse (NIDA)","NIH","100491750","phase-1-omar-opioid-use-disorder-100491750",false,"NCT05683184","OMAR Opioid Use Disorder","Characterization of CB1 Receptors Using [11-C]OMAR in Opioid Use Disorder","Inclusion Criteria:\n\n* Able to provide informed consent\n* Male and female 18 years and older\n* DSM-5 diagnosis of opioid use disorder (for OUD group)\n* Physically healthy i.e., no clinically unstable medical conditions\n* Written informed consent and have capacity to consent and comply with study procedures\n\nExclusion Criteria:\n\n* Current neuro-psychiatric illness or severe systemic disease (opioid use disorder is permitted in the OUD group).\n* Presence of ferromagnetic metal in the body or heart pacemaker\n* Have had exposure to ionizing radiation that in combination with the study tracer would result in a cumulative exposure that exceeds recommended exposure limits\n* Are claustrophobic",true,"ALL","18 Years",{"count":76,"type":77},30,"ESTIMATED","INTERVENTIONAL",[80],"PHASE1","The goal of this research study is to examine the endocannabinoid (eCB) function in vivo in individuals with opioid use disorder (OUD) by measuring cannabinoid receptor 1 (CB1R) availability.",[83,14],"Healthy Control","2026-04-26",{"date":86,"type":87},"2026-04-28","ACTUAL",{"date":89,"type":87},"2023-03-10",{"date":91,"type":77},"2026-12-15",{"name":5,"class":6},1]